Prelude Therapeutics (PRLD) Cash from Operations Growth (3y) (2022 - 2026)
Prelude Therapeutics (PRLD) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | - |
| 10 | Prelude Therapeutics | 332.56 Mn | 187.96 Mn | - | 10.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.39% |
| Dec 31, 2025 | 44.36% |
| Sep 30, 2025 | 2.21% |
| Jun 30, 2025 | -12.19% |
| Mar 31, 2025 | -16.06% |
| Dec 31, 2024 | 6.89% |
| Sep 30, 2024 | -7.83% |
| Jun 30, 2024 | -5.01% |
| Mar 31, 2024 | -25.34% |
| Dec 31, 2023 | -16.67% |
| Sep 30, 2023 | -27.11% |
| Jun 30, 2023 | -45.94% |
| Mar 31, 2023 | -44.82% |
| Dec 31, 2022 | -39.37% |